Novo Nordisk (NVO) CEO Lars Fruergaard Jorgensen has said that starting doses of the company's weight-loss drugs will be reduced somewhat until the end of the year, as the company plans to gradually expand and bring more and more products to the US. While demand for Wegovy is soaring, there have been supply issues, particularly in the US.
 
(MT Newswires)

Bloomberg videos